Nasdaq · CIK 0001567264
INTS INTENSITY THERAPEUTICS, INC.
Insider trading from SEC Form 4. Last filing Jul 20, 2026.
In brief
INTENSITY THERAPEUTICS, INC. (INTS) has 24 SEC Form 4 filings on file from 7 insiders, the latest filed on Jul 20, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at INTENSITY THERAPEUTICS, INC., scored.
Transactions
Every row filed, 24 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 16, 2026 | Thomas I H Dubin director | AGrant or award Stock Option (right to buy Common Stock)derivative | +5,500 | $0.00 | $0 | 5,500 | Jul 20, 2026 |
| Jul 16, 2026 | Daniel Donovan director | AGrant or award Stock Option (right to buy Common Stock)derivative | +5,500 | $0.00 | $0 | 5,500 | Jul 20, 2026 |
| Jul 16, 2026 | Mark A Goldberg director | AGrant or award Stock Option (right to buy Common Stock)derivative | +5,500 | $0.00 | $0 | 5,500 | Jul 20, 2026 |
| Jul 16, 2026 | Joseph Talamo Chief Financial Officer | AGrant or award Stock Option (right to buy Common Stock)derivative | +34,000 | $0.00 | $0 | 34,000 | Jul 20, 2026 |
| Jul 16, 2026 | Emer Leahy director | AGrant or award Stock Option (right to buy Common Stock)derivative | +5,500 | $0.00 | $0 | 5,500 | Jul 20, 2026 |
| Jul 16, 2026 | John M Wesolowski Principal Accounting Officer | AGrant or award Stock Option (right to buy Common Stock)derivative | +11,000 | $0.00 | $0 | 11,000 | Jul 20, 2026 |
| Jul 16, 2026 | Lewis H Bender President and CEO | AGrant or award Stock Option (right to buy Common Stock)derivative | +78,000 | $0.00 | $0 | 78,000 | Jul 20, 2026 |
| Jun 30, 2026 | Joseph Talamo Chief Financial Officer | AGrant or award Common Stock, $0.0001 Par Value | +1,093 | $3.49 | $3,809 | 2,239 | Jul 1, 2026 |
| Jun 30, 2026 | John M Wesolowski Principal Accounting Officer | AGrant or award Common Stock, $0.0001 Par Value | +3,688 | $3.49 | $13k | 7,102 | Jul 1, 2026 |
| Mar 26, 2026 | Lewis H Bender President and CEO | AGrant or award Common Stock, $0.0001 Par Value | +37,749 | $6.11 | $231k | 118,549 | Mar 30, 2026 |
| Dec 31, 2025 | Joseph Talamo Chief Financial Officer | AGrant or award Common Stock, $0.0001 Par Value | +14,482 | $0.26 | $3,794 | 28,661 | Jan 5, 2026 |
| Dec 31, 2025 | John M Wesolowski Principal Accounting Officer | AGrant or award Common Stock, $0.0001 Par Value | +8,918 | $0.26 | $2,337 | 85,354 | Jan 5, 2026 |
| Jun 30, 2025 | Joseph Talamo Chief Financial Officer | AGrant or award Common Stock, $0.0001 Par Value | +14,179 | $0.26 | $3,701 | 14,179 | Jul 2, 2025 |
| Jun 30, 2025 | John M Wesolowski Principal Accounting Officer | AGrant or award Common Stock, $0.0001 Par Value | +69,745 | $0.26 | $18k | 76,436 | Jul 2, 2025 |
| May 2, 2025 | Lewis H Bender President and CEO | AGrant or award Stock Option (right to buy Common Stock)derivative | +700,000 | $0.00 | $0 | 700,000 | May 6, 2025 |
| May 2, 2025 | Thomas I H Dubin director | AGrant or award Stock Option (right to buy Common Stock)derivative | +50,000 | $0.00 | $0 | 50,000 | May 6, 2025 |
| May 2, 2025 | Daniel Donovan director | AGrant or award Stock Option (right to buy Common Stock)derivative | +50,000 | $0.00 | $0 | 50,000 | May 6, 2025 |
| May 2, 2025 | Mark A Goldberg director | AGrant or award Stock Option (right to buy Common Stock)derivative | +50,000 | $0.00 | $0 | 50,000 | May 6, 2025 |
| May 2, 2025 | Joseph Talamo Chief Financial Officer | AGrant or award Stock Option (right to buy Common Stock)derivative | +300,000 | $0.00 | $0 | 300,000 | May 6, 2025 |
| May 2, 2025 | John M Wesolowski Principal Accounting Officer | AGrant or award Stock Option (right to buy Common Stock)derivative | +100,000 | $0.00 | $0 | 100,000 | May 6, 2025 |
| May 2, 2025 | Emer Leahy director | AGrant or award Stock Option (right to buy Common Stock)derivative | +50,000 | $0.00 | $0 | 50,000 | May 6, 2025 |
| May 2, 2025 | John M Wesolowski Principal Accounting Officer | AGrant or award Stock Option (right to buy Common Stock)derivative | +100,000 | $0.00 | $0 | 100,000 | May 6, 2025 |
| Oct 21, 2024 | Joseph Talamo Chief Financial Officer | AGrant or award Stock Option (right to buy Common Stock)derivative | +427,379 | $0.00 | $0 | 427,379 | Oct 23, 2024 |
| Oct 21, 2024 | John M Wesolowski Principal Accounting Officer | AGrant or award Stock Option (right to buy Common Stock)derivative | +70,028 | $0.00 | $0 | 70,028 | Oct 23, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Lewis H BenderPresident and CEO
- Thomas I H Dubindirector
- Daniel Donovandirector
- Mark A Goldbergdirector
- Emer Leahydirector
- Joseph TalamoChief Financial Officer
- John M WesolowskiPrincipal Accounting Officer
Questions about INTS
Answered from the filings on this page, as of the latest one.
Are insiders buying INTS?
No. In the last 90 days no insider at INTENSITY THERAPEUTICS, INC. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade INTS on the open market?
No open-market trade has been scored at INTENSITY THERAPEUTICS, INC.. The latest Form 4 on file was filed on Jul 20, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at INTENSITY THERAPEUTICS, INC.?
7 people have filed a Form 4 at INTENSITY THERAPEUTICS, INC., among them Lewis H Bender (President and CEO), Thomas I H Dubin (director), Daniel Donovan (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.